Kartesia supports the global expansion of Symbios

Kartesia, the European specialist provider of financing solutions for small and mid-sized companies, is pleased to announce that it has provided a flexible financing package to support Symbios Orthopédie SA (“Symbios” or “the Company”) in its ambitious growth strategy.

Founded in 1989 by the Plé family in Switzerland, Symbios is a world-leading medical technology company specializing in patient-specific orthopaedic hip and knee implants. Positioned within the prestigious medical industry cluster in Yverdon-les-Bains, Symbios leverages unique know-how and biomedical engineering resources. The Company designs, manufactures, and distributes knee and hip implants which are customized for each patient’s individual anatomy. Their best-in-class innovation capabilities, exemplified by the successful ORIGIN® patient-specific knee implant, drive their high double-digit growth in a mature orthopaedic market. The ORIGIN® knee was launched in late 2018 after 7 years of R&D efforts and was developed with the support of industry-leading surgeons.

Through its unique “implant-in-a-box” offering, Symbios stands out with a disruptive value proposition for all stakeholders (including patients, surgeons and health institutions), supported by a digital-centric industrial model. Symbios, with over 30 years of industry experience, has established a strong market position in EMEA. Recently, it expanded internationally into Australia and will soon do so in the US.

This debt financing is provided by Kartesia Credit Opportunities (“KCO”) strategy. The deal team at Kartesia included Matthieu Delamaire, Julien Rigon, Alexis Midol and Clémence Demière.

Julien Rigon, Partner and Head of France comments: “We are proud to accompany Symbios on its new growth chapter, alongside Florent Plé and his seasoned management team. The Company benefits from several key market differentiators, notably its unmatched patient-specific implant offering, a state-of-the-art new industrial facility and strong innovation capabilities in a mature industry. Additionally, we were impressed by the level of organizational maturity of Symbios on the manufacturing, quality and regulatory fronts. All of which are fundamental to thrive in this industry. We are confident that our financing solution perfectly matches the Group’s ambition to strengthen its position in Europe and accelerate its international expansion, especially in the US”.

Florent Plé, CEO of Symbios, adds: “I am very pleased to welcome Kartesia as a partner in our expanding business. Their experienced team and flexible financing will enable us to accelerate our growth in existing and new strategic markets such as the US, as well as to continue developing innovative solutions to improve the quality of life of orthopaedic patients worldwide”.